Drug intelligence / Profile preview

IC

Development stage: Unknown
Lead developer: Health Ever Bio-Tech
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravesical

Overview

IC is a nanoparticle-based therapeutic being developed by Health Ever Bio-Tech for the treatment of interstitial cystitis. The drug utilizes a nanoparticle carrier modality designed for intravesical delivery directly into the bladder. This delivery system aims to overcome the bladder's permeability barrier and increase the retention time of the therapeutic agent within the bladder, addressing the chronic inflammation and pelvic pain associated with interstitial cystitis. As of current reports, the specific active pharmaceutical ingredient and molecular target remain undisclosed, and the program is in early-stage clinical development.

Other names: IC-Health Ever Bio-Tech-nanoparticle carrier-Interstitial cystitis

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on IC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IC.

Explore the full profile